Details
Stereochemistry | RACEMIC |
Molecular Formula | C5H8NO3S.Na |
Molecular Weight | 185.177 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(S)C(=O)NCC([O-])=O
InChI
InChIKey=BKHJWWRUVITKEE-UHFFFAOYSA-M
InChI=1S/C5H9NO3S.Na/c1-3(10)5(9)6-2-4(7)8;/h3,10H,2H2,1H3,(H,6,9)(H,7,8);/q;+1/p-1
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=494a714e-923c-cd57-df6c-12886afb265aCurator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB06823
https://en.wikipedia.org/wiki/Tiopronin
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=494a714e-923c-cd57-df6c-12886afb265a
Curator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB06823
https://en.wikipedia.org/wiki/Tiopronin
Tiopronin is a prescription thiol drug used primarily in the treatment of severe homozygous cystinuria. Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation. Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation. It is used after a failure of the non-pharmacological first line treatment consisting of increased fluid intake, restriction of sodium and protein, and urinary alkalinization. As cystinuria is a relatively rare disease, tiopronin is classified as an orphan drug and is not patented in the United States. It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects. Tiopronin is dosed on an individual basis using close monitoring of urinary cystine concentrations and urinary output. Tiopronin is a chelating agent. It works by removing extra cystine (the cause of kidney stones) from the urine, which keeps the kidney stones from forming. It works by reacting with urinary cysteine to form a more soluble, disulfide linked, tiopronin-cysteine complex.
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.6 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1505618 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIOPRONIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
29 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1505618 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIOPRONIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.7 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1505618 |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
TIOPRONIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1 g 3 times / day multiple, oral Highest studied dose Dose: 1 g, 3 times / day Route: oral Route: multiple Dose: 1 g, 3 times / day Sources: |
unhealthy, 43-74 n = 9 Health Status: unhealthy Condition: aneurysmal subarachnoid hemorrhage Age Group: 43-74 Sex: M+F Population Size: 9 Sources: |
|
1 g 1 times / day multiple, oral Highest studied dose Dose: 1 g, 1 times / day Route: oral Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, 56.7 n = 28 Health Status: unhealthy Condition: rheumatoid arthritis Age Group: 56.7 Sex: M+F Population Size: 28 Sources: |
Other AEs: Proteinuria, Stomatitis... Other AEs: Proteinuria (4 patients) Sources: Stomatitis (3 patients) Itching (2 patients) Discomfort epigastric (1 patient) |
0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Other AEs: Anemia, Nausea... Other AEs: Anemia (6%) Sources: Nausea (12%) Emesis Diarrhea (6%) Abdominal pain (6%) Oral ulceration (18%) Fever Weakness (12%) Fatigue Edema peripheral (6%) Chest pain (6%) Anorexia Arthralgia (12%) Proteinuria (6%) Impotence (6%) Cough (6%) Rash (12%) Ecchymosis Pruritus (6%) Urticaria Skin wrinkling (6%) |
0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Other AEs: Anemia, Nausea... Other AEs: Anemia (2%) Sources: Nausea (25%) Emesis (10%) Diarrhea (18%) Abdominal pain Oral ulceration (12%) Fever (8%) Weakness (4%) Fatigue (14%) Edema peripheral (6%) Chest pain Anorexia (8%) Arthralgia Proteinuria (10%) Impotence Cough Rash (14%) Ecchymosis (6%) Pruritus (4%) Urticaria (8%) Skin wrinkling (6%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Discomfort epigastric | 1 patient | 1 g 1 times / day multiple, oral Highest studied dose Dose: 1 g, 1 times / day Route: oral Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, 56.7 n = 28 Health Status: unhealthy Condition: rheumatoid arthritis Age Group: 56.7 Sex: M+F Population Size: 28 Sources: |
Itching | 2 patients | 1 g 1 times / day multiple, oral Highest studied dose Dose: 1 g, 1 times / day Route: oral Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, 56.7 n = 28 Health Status: unhealthy Condition: rheumatoid arthritis Age Group: 56.7 Sex: M+F Population Size: 28 Sources: |
Stomatitis | 3 patients | 1 g 1 times / day multiple, oral Highest studied dose Dose: 1 g, 1 times / day Route: oral Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, 56.7 n = 28 Health Status: unhealthy Condition: rheumatoid arthritis Age Group: 56.7 Sex: M+F Population Size: 28 Sources: |
Proteinuria | 4 patients | 1 g 1 times / day multiple, oral Highest studied dose Dose: 1 g, 1 times / day Route: oral Route: multiple Dose: 1 g, 1 times / day Sources: |
unhealthy, 56.7 n = 28 Health Status: unhealthy Condition: rheumatoid arthritis Age Group: 56.7 Sex: M+F Population Size: 28 Sources: |
Anorexia | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
|
Ecchymosis | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
|
Emesis | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
|
Fatigue | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
|
Fever | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
|
Urticaria | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
|
Arthralgia | 12% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Nausea | 12% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Rash | 12% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Weakness | 12% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Oral ulceration | 18% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Abdominal pain | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Anemia | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Chest pain | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Cough | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Diarrhea | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Edema peripheral | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Impotence | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Proteinuria | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Pruritus | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Skin wrinkling | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 17 Health Status: unhealthy Condition: cystinuria Population Size: 17 Sources: |
Abdominal pain | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
|
Arthralgia | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
|
Chest pain | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
|
Cough | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
|
Impotence | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
|
Emesis | 10% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Proteinuria | 10% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Oral ulceration | 12% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Fatigue | 14% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Rash | 14% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Diarrhea | 18% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Anemia | 2% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Nausea | 25% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Pruritus | 4% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Weakness | 4% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Ecchymosis | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Edema peripheral | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Skin wrinkling | 6% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Anorexia | 8% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Fever | 8% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
Urticaria | 8% | 0.267 g 3 times / day multiple, oral Recommended Dose: 0.267 g, 3 times / day Route: oral Route: multiple Dose: 0.267 g, 3 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: cystinuria Population Size: 49 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties. | 2000 Jul-Aug |
|
Brief murine myocardial I/R induces chemokines in a TNF-alpha-independent manner: role of oxygen radicals. | 2001 Dec |
|
Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. | 2001 Dec 14 |
|
The cytotoxic effects of diesel exhaust particles on human pulmonary artery endothelial cells in vitro: role of active oxygen species. | 2001 Mar 1 |
|
Attenuation of the acute adriamycin-induced cardiac and hepatic oxidative toxicity by N-(2-mercaptopropionyl) glycine in rats. | 2001 Nov |
|
A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria. | 2001 Oct |
|
15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. | 2001 Oct 12 |
|
Effect of treatment on ventricular function and troponin I proteolysis in reperfused myocardium. | 2002 Apr |
|
Isoflurane preconditions myocardium against infarction via release of free radicals. | 2002 Apr |
|
The relative order of mK(ATP) channels, free radicals and p38 MAPK in preconditioning's protective pathway in rat heart. | 2002 Aug 15 |
|
Acetylcholine leads to free radical production dependent on K(ATP) channels, G(i) proteins, phosphatidylinositol 3-kinase and tyrosine kinase. | 2002 Aug 15 |
|
Oxidant species trigger late preconditioning against myocardial stunning in conscious rabbits. | 2002 Jan |
|
Yellow nail syndrome associated with thiol compound therapy for rheumatoid arthritis. Two case reports. | 2002 Jun |
|
Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart. | 2002 May |
|
The new MATH: homology suggests shared binding surfaces in meprin tetramers and TRAF trimers. | 2002 Oct 23 |
|
Mitochondrial adenosine triphosphate-regulated potassium channel opening acts as a trigger for isoflurane-induced preconditioning by generating reactive oxygen species. | 2003 Apr |
|
Urinary excretion of total cystine and the dibasic amino acids arginine, lysine and ornithine in relation to genetic findings in patients with cystinuria treated with sulfhydryl compounds. | 2003 Dec |
|
Au nanoparticle-enhanced surface plasmon resonance sensing of biocatalytic transformations. | 2003 Dec 15 |
|
Effects of N-(2-mercaptopropionyl)-glycine on mitochondrial function in ischemic-reperfused heart. | 2003 Feb |
|
Modifications of myosin-regulatory light chain correlate with function of stunned myocardium. | 2003 Jul |
|
Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors. | 2003 Jul |
|
Protective effect of N2-mercaptopropionylglycine on rats and dogs liver during ischemia/reperfusion process. | 2003 Jul-Sep |
|
[Cystinuria - Cystine Stones: Recommendations for Diagnosis, Therapy and Follow-up]. | 2003 Mar |
|
The cardioprotective effect of sevoflurane depends on protein kinase C activation, opening of mitochondrial K(+)(ATP) channels, and the production of reactive oxygen species. | 2003 Nov |
|
Polyherbal extract of septilin protects mice against whole body lethal dose of gamma radiation. | 2004 Aug |
|
Yellow nail syndrome in rheumatoid arthritis: a drug-induced disease? | 2004 Aug |
|
Delayed cardioprotection is mediated via a non-peptide delta opioid agonist, SNC-121, independent of opioid receptor stimulation. | 2004 Jan |
|
Oligonucleotide-displaced organic monolayer-protected silver nanoparticles and enhanced luminescence of their salted aggregates. | 2004 Jul 1 |
|
Reactive oxygen species precede protein kinase C-delta activation independent of adenosine triphosphate-sensitive mitochondrial channel opening in sevoflurane-induced cardioprotection. | 2004 Mar |
|
Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts. | 2004 Mar |
|
The effects of ionizing radiation on DNA: the role of thiols as radioprotectors. | 2004 Mar 26 |
|
Protective effects of alpha-tocopherol and tiopronin against cisplatin-induced ototoxicity. | 2004 May |
|
Effect of change in cellular GSH levels on mitochondrial damage and cell viability loss due to mitomycin c in small cell lung cancer cells. | 2004 Nov 1 |
|
HPLC study of tyrosinase inhibition by thiopronine. | 2004 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=494a714e-923c-cd57-df6c-12886afb265a
Curator's Comment: Urinary cystine should be measured at 1 month after THIOLA treatment, and every 3 months thereafter. THIOLA dosage should be readjusted depending on the urinary cystine value.
THIOLA (Tiopronin) may be begun at a dosage of 800 mg/day in adult patients with cystine stones. In a multiclinic trial, average dose of THIOLA was about 1000 mg/day. In children, initial dosage may be based on 15 mg/kg/day. Whenever possible, THIOLA should be given in divided doses 3 times/day at least one hour before or 2 hours after meals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/8975767
Tiopronin (2 mM) completely prevents the Cisplatin-induced increase in enzyme leakage and substantially blocks the decrease of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction caused by Cisplatin. Tiopronin also significantly protects the renal slices from cisplatin-induced toxic effects. Tiopronin protects against cisplatin-induced nephrotoxicity by acting as an alternative target for Cisplatin both intra- and extracellularly and thus protects against cisplatin-induced depletion of glutathione in the kidney cell
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
23672295
Created by
admin on Sat Dec 16 07:39:14 GMT 2023 , Edited by admin on Sat Dec 16 07:39:14 GMT 2023
|
PRIMARY | |||
|
2015-25-0
Created by
admin on Sat Dec 16 07:39:14 GMT 2023 , Edited by admin on Sat Dec 16 07:39:14 GMT 2023
|
PRIMARY | |||
|
SUB04881MIG
Created by
admin on Sat Dec 16 07:39:14 GMT 2023 , Edited by admin on Sat Dec 16 07:39:14 GMT 2023
|
PRIMARY | |||
|
33F0GJ6GBH
Created by
admin on Sat Dec 16 07:39:14 GMT 2023 , Edited by admin on Sat Dec 16 07:39:14 GMT 2023
|
PRIMARY | |||
|
DTXSID20942195
Created by
admin on Sat Dec 16 07:39:14 GMT 2023 , Edited by admin on Sat Dec 16 07:39:14 GMT 2023
|
PRIMARY | |||
|
100000084629
Created by
admin on Sat Dec 16 07:39:14 GMT 2023 , Edited by admin on Sat Dec 16 07:39:14 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD